Business
Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its core product APL-1702 (trade name: CEVIRA®), has received the Drug Registration Certificate from China's National Medical Products Administration (NMPA), enabling commercial launch in China.
About this update from Photocure Asa
[{"type":"text","content":"OSLO, Norway, March 3, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its core product APL-1702 (trade name: CEVIRA®), has received the Drug Registration Certificate from China's National Medical Products Administration (NMPA), enabling commercial launch in China. ","length":390,"tagName":"p"},{"type":"text","content":"Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure. With Cevira's regulatory approval in China, Photocure is eligible for a milestone payment with further sales milestones based on future revenue.","length":356,"tagName":"p"},{"type":"text","content":"The announcement from Asieris states: "As the world's first non-surgical, non-invasive therapy for patients with cervical intraepithelial neoplasia grade 2 (CIN2), APL-1702 is expected to fill a critical clinical gap in this therapeutic area and redefine a massive, previously underserved market for non-invasive cervical disease treatment.","length":349,"tagName":"p"},{"type":"text","content":"In the absence of other approved non-invasive treatment options, APL-1702 has the potential to reshape a treatment landscape long dominated by surgical and other invasive or minimally invasive interventions. It will enable a shift from a "one-size-fits-all" approach toward one that prioritizes non-invasive therapy, offering a breakthrough solution to current clinical challenges."","length":397,"tagName":"p"},{"type":"text","content":""This regulatory milestone is a substantial achievement for a non-surgical organ-sparing treatment option which addresses an important unmet medical need," said Anders Neijber, Photocure's Chief Medical Officer","length":229,"tagName":"p"},{"type":"text","content":"Read Asieris' full media release here: https://asieris.com/asieris-cevira-approved-in-china-as-first-in-class-non-invasive-therapy-for-cervical-precancerous-lesions/","length":169,"tagName":"p"},{"type":"text","content":"Note to editors:","length":16,"tagName":"p"},{"type":"text","content":"All trademarks mentioned in this release are protected by law and are re...